Spring LM - Search Results

1

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Abelman RO, Wu B, Barnes H, Medford A, Norden B, Putur A, Bitman E, Thant W, Liu T, Weipert C, Fell G, Spring LM, Wander SA, Moy B, Vidula N, Isakoff SJ, Varkaris A, Juric D, Corcoran RB, Ellisen LW, Bardia A. Abelman RO, et al. Among authors: spring lm. Clin Cancer Res. 2025 May 15;31(10):1966-1974. doi: 10.1158/1078-0432.CCR-24-2771. Clin Cancer Res. 2025. PMID: 39745368 Free PMC article.

2

Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.

Spring L, Bardia A, Modi S. Spring L, et al. Discov Med. 2016 Jan;21(113):65-74. Discov Med. 2016. PMID: 26896604 Free PMC article.

3

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Spring LM, et al. JAMA Oncol. 2016 Nov 1;2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897. JAMA Oncol. 2016. PMID: 27367583 Free PMC article.

4

SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?

Spring L, Bardia A. Spring L, et al. Lancet Oncol. 2017 May;18(5):564-565. doi: 10.1016/S1470-2045(17)30106-7. Epub 2017 Mar 15. Lancet Oncol. 2017. PMID: 28314690 No abstract available.

5

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Spring LM, Zangardi ML, Moy B, Bardia A. Spring LM, et al. Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Oncologist. 2017. PMID: 28706010 Free PMC article. Review.

6

Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

Zangardi ML, Spring LM, Blouin GC, Bardia A. Zangardi ML, et al. Among authors: spring lm. Expert Rev Clin Pharmacol. 2017 Nov;10(11):1169-1176. doi: 10.1080/17512433.2017.1376653. Epub 2017 Sep 18. Expert Rev Clin Pharmacol. 2017. PMID: 28875723 Review.

7

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. Spring L, et al. J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158. J Natl Compr Canc Netw. 2017. PMID: 28982747

8

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A. Condorelli R, et al. Ann Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784. Ann Oncol. 2018. PMID: 29236940 Free article.

9

Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.

Spring L, Bardia A. Spring L, et al. Clin Cancer Res. 2018 Jul 1;24(13):2981-2983. doi: 10.1158/1078-0432.CCR-18-0463. Epub 2018 Apr 23. Clin Cancer Res. 2018. PMID: 29685881

10

Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer.

Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K. Abraham E, et al. Clin J Oncol Nurs. 2018 Jun 1;22(3):E71-E77. doi: 10.1188/18.CJON.E71-E77. Clin J Oncol Nurs. 2018. PMID: 29781452 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters